Target intelligence / Profile preview

Nocturnin (NOCT)

Target
NOCT
Molecular classification
Enzyme, Phosphatase (specifically, NADP(H) 2′-phosphatase), Endonuclease/Exonuclease/Phosphatase family (EEP), Exoribonuclease (historic/structural annotation)
01

Overview

Nocturnin is a phosphatase enzyme encoded by the NOCT gene on human chromosome 4, regulated by the circadian clock, with expression peaking in the early evening[4]. Structurally, it is part of the endonuclease/exonuclease/phosphatase (EEP) family and closely related to CCR4-class deadenylases such as PDE12 and CNOT6L, as well as the DNA repair enzyme TDP2[2][3]. Nocturnin’s previously hypothesized deadenylase activity was not supported by later studies; instead, it acts as an NADP(H) 2′-phosphatase, directly regulating NADP+ and NADPH levels, a function conserved across species[4]. It plays a key role in aligning cellular metabolism to the circadian rhythm and affects metabolic homeostasis—mice lacking Nocturnin are resistant to diet-induced obesity, and genetic variation in humans has been linked to cancer risk and body mass regulation[4][5]. No direct pharmacological drugs or inhibitors are reported as of yet. Nocturnin localizes to the mitochondria and cytoplasm[4], modulating metabolic enzymes in a time-of-day dependent manner. Key structural features include a globular α/β sandwich fold, a magnesium ion in the catalytic center, and unique surface and active site properties distinct from other CCR4-like deadenylases, contributing to its substrate specificity[2][3][1]. If further details or more precise molecular or pharmacological information become known or are required for broad drug databases, consult recent literature as Nocturnin’s enzymatic function has only recently been clarified.

Other names
CCRN4LCCR4Carbon catabolite repression 4-like proteinCCR4LCcr4cNOCcircadian deadenylase NOCCCR4 protein homologCCR4-like (carbon catabolite repression 4, S. cerevisiae)curled (Drosophila)
02

Biological functions

Circadian clock functionMetabolic regulationRegulation of gene expressionNADP(H) metabolismPotential mRNA turnover
03

Disease associations

Metabolic disorders (e.g., obesity, weight gain)Cancer (e.g., non–small cell lung cancer)Other (circadian disruption)
04

Biomarkers

Body mass index–related polymorphismsGene expression rhythmicity (circadian biomarker potential)

Beyond the preview

Go deeper on Nocturnin (NOCT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nocturnin (NOCT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call